By Digifin Pty Ltd · About this coverage
Key Points
- Estimated China label offtake at ~50% of pre-supply chain disruption levels, up from ~40% in August
- FY27 revenue growth of mid single digit percent expected, with 1H27 slightly down on 1H26
- Underlying EBITDA margin expected to be approximately 15%, with 1H27 materially down
- Total IMF sales expected to be broadly similar to FY26
- One-off transformation costs now expected to be ~$15 million in FY27

About a2 Milk (ASX:A2M)
The a2 Milk Company Limited is a dairy nutrition company headquartered in Auckland, with its securities quoted on the ASX under the code A2M and on the NZX. It markets infant milk formula, liquid milk and other nutritional products made from milk containing only the A2 beta-casein protein type. Its main markets are China and other parts of Asia, Australia and New Zealand, and the United States.
The a2 Milk (ASX:A2M) Company updated its FY27 outlook and China infant milk formula recovery at its Annual Meeting, with Group revenue and EBITDA now expected to be materially weighted to 2H27.
The company says shortfalls of China label IMF product in 4Q26 forced a large proportion of existing users to switch to alternative brands, with flow-on effects expected in FY27. Estimated China label offtake has recovered to ~50% of pre-supply chain disruption levels, up from ~40% in August 2026. Total IMF sales are expected to be broadly similar to FY26, with China label and English label expected to recover gradually over FY27, supported by two new China label products, the updated a2 Platinum product and increased marketing, particularly in 1H27. Against FY26, on a continuing operations basis, the company expects revenue growth of mid single digit percent, with 1H27 revenue slightly down on 1H26, and an Underlying EBITDA margin of approximately 15%, with 1H27 materially down on 1H26. It also expects capital expenditure of approximately $70 million. The company says the a2 Platinum transition to a2 Pōkeno is on track, with one-off transformation costs now expected to be ~$15 million in FY27 and none in FY28.
The company says a range of outcomes is possible depending on the rate of IMF recovery. The China importation requirements affecting a2 Genesis remain unresolved, and the release does not quantify the effect of the weaker NZD, saying the earnings uplift is offset by hedge losses.
Source: The a2 Milk Company Limited (ASX:A2M), 19 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.
